@bermaninstitute

A broad diversity of patient advocacy groups have expressed alarm at Judge Kacsmaryk's unprecedented decision

“The implications of this ruling go far beyond #mifepristone,” read a statement of opposition signed by 30 organizations representing those with serious health conditions.

They warned, “If this judge’s ruling is allowed to stand, patients may no longer have the security of knowing that determinations about drug safety ultimately lie with the experts.”

Also objecting are pharmaceutical companies that recognize the threat to innovation posed by arbitrary judicial orders.

The interim director of the biotech organization #BIO described the decision as **an assault on science**, while the pharmaceutical organization #PhRMA expressed **serious concerns with any court substituting its opinion for the FDA’s expert approval decision-making**